Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Leadership Shift | Explore how new CEO David Pacitti's industry expertise could drive Avanos Medical's growth and strategic realignment in the medical device secto |
Financial Crossroads | Delve into Avanos Medical's mixed financial performance, with Q1 2025 growth offset by lowered EPS guidance and anticipated tariff impacts |
Market Positioning | Learn about Avanos Medical's efforts to refine its business priorities and enhance its competitive stance amid challenges in key product segments |
Future Prospects | Analysts view 2025 as a transition year for Avanos Medical, with a cautious stance reflected in the average price target of around $13.20 |
Metrics to compare | AVNS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVNSPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | 150.5x | −0.7x | |
PEG Ratio | 0.00 | 1.17 | 0.00 | |
Price/Book | 0.7x | 7.5x | 2.6x | |
Price / LTM Sales | 0.8x | 4.0x | 3.3x | |
Upside (Analyst Target) | 23.7% | 72.6% | 37.1% | |
Fair Value Upside | Unlock | 13.1% | 4.7% | Unlock |